Unity Biotechnology (NASDAQ: UBX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.260 | -0.280 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Unity Biotechnology (NASDAQ: UBX) through any online brokerage.
Other companies in Unity Biotechnology’s space includes: Acurx Pharmaceuticals (NASDAQ:ACXP), Connect Biopharma Hldgs (NASDAQ:CNTB), Celyad Oncology (NASDAQ:CYAD), Evaxion Biotech (NASDAQ:EVAX) and Applied Genetic (NASDAQ:AGTC).
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by Citigroup on Tuesday, May 17, 2022. The analyst firm set a price target for 5.00 expecting UBX to rise to within 12 months (a possible 715.13% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Unity Biotechnology (NASDAQ: UBX) is $0.6134 last updated Today at July 5, 2022, 3:17 PM UTC.
There are no upcoming dividends for Unity Biotechnology.
Unity Biotechnology’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Unity Biotechnology.
Unity Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.